Paragon Tech Inc (PGNT) 1.5300 $PGNT Paragon

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Paragon Tech Inc (PGNT) 1.5300 $PGNT

Paragon Technologies News Release
ACCESSWIRE - Fri Aug 12, 10:16AM CDT
EASTON, PA / ACCESSWIRE / August 12, 2016 / Paragon Technologies, Inc. (OTC Pink: PGNT), a holding company, announced its results for the second quarter ended June 30, 2016 on August 12, 2016.

Paragon Calls on Rubicon to Explain Appointment of Director with Questionable Record
ACCESSWIRE - Thu Jun 02, 2:32PM CDT
ATLANTA, GA / ACCESSWIRE / June 2, 2016 / Paragon Technologies, Inc., which has initiated a proxy contest at the annual meeting of Rubicon Technology, Inc. (NASDAQ: RBCN) scheduled to be held on June 24, 2016, today called on Rubicon to explain the unilateral appointment by the incumbent Board of a new director with a questionable record in the midst of an election process, bypassing a vote of shareholders.
RBCN: 0.63 (+0.01)

Paragon Technologies Responds to Rubicon's Weak Turnaround Plan
ACCESSWIRE - Tue May 31, 12:03PM CDT
ATLANTA, GA / ACCESSWIRE / May 31, 2016 /
RBCN: 0.63 (+0.01)

Paragon Asks Rubicon Technology Board to Stop Its $1 Million Proxy Campaign to Remain Entrenched
ACCESSWIRE - Tue May 24, 3:10PM CDT
ATLANTA, GA / ACCESSWIRE / May 24, 2016 / Paragon Technologies, Inc. (OTC: PGNT) would like to make shareholders aware of the extreme financial expense that the Rubicon Technology (NASDAQ: RBCN) Board of Directors is incurring in order to further entrench themselves as directors.
RBCN: 0.63 (+0.01)

Paragon Technologies Releases Chairman's Annual Letter to Shareholders
ACCESSWIRE - Thu May 19, 2:36PM CDT
EASTON, PA / ACCESSWIRE / May 19, 2016 / Paragon Technologies, Inc. (OTC: PGNT) 2015 Annual Letter to Shareholders is now available on the company's website, www.pgntgroup.com. All Paragon shareholders are encouraged to read it. Shareholders can access the letter by clicking the following link:

Paragon Technologies Initiates Proxy Contest at Rubicon Technology, Inc.
BusinessWire - Fri Apr 22, 3:00PM CDT
Paragon Technologies, Inc. today announced that it has initiated a proxy contest to elect two new directors at the 2016 annual meeting of shareholders of Rubicon Technology, Inc. (NASDAQ: RBCN). Paragon's director candidates would replace Don N. Aquilano and Donald R. Caldwell, the two directors up for election on Rubicon's five-member staggered board.
RBCN: 0.63 (+0.01)

Rubicon Technology Comments on Director Nominations From Paragon Technologies
BusinessWire - Mon Apr 18, 8:00AM CDT
Rubicon Technology, Inc. (Nasdaq: RBCN) ("Rubicon" or the "Company", today confirmed that Paragon Technologies, Inc. ("Paragon", which owns 30,000 (approximately 0.1%) of the outstanding shares of Rubicon, has submitted notice to nominate two candidates, Hesham M. Gad and Jack H. Jacobs, to stand for election to the Rubicon Board of Directors at the Company's 2016 Annual Meeting of Stockholders.
RBCN: 0.63 (+0.01)

Paragon Technologies Reports Third Quarter Results
PR Newswire - Fri Nov 14, 12:40PM CST
Paragon Technologies, Inc. (OTC Pink: PGNT), a holding company, today announces its results for the third quarter of 2014.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pan-Mass Challenge Gifts $80M to Dana-Farber for 2026

Updated Category News Views 135

A Momentous Gift in a Crunch Time for Cancer Research Biking and philanthropy might seem like an odd duo, but let me tell you, the Pan-Mass Challenge (PMC) is making that partnership look like peanut butter and jelly. This year, PMC rolled out a jaw-dropping $80 million gift to the Dana-Farber Cancer Institute. You heard right—eighty million smackeroos. Talk about going...

Continue Reading
Novo's CagriSema Trials Show Promising Weight Loss

Updated Category News Views 220

Decoding CagriSema's Promise Let me tell you, when those corporate folks from Novo Nordisk announce something big like their investigational drug CagriSema at ObesityWeek® 2026, it’s time to take notice. This isn’t just your average press release about some new weight loss fad. We’re talking about a phase 3 REDEFINE 1 trial that opens up a treasure chest of data...

Continue Reading
Portillo's Faces Class Action: Investor Losses at Stake

Updated Category News Views 210

Investor Tensions Rise as Portillo's Inc. Lawsuit Unfolds Investment ain't all sunshine and rainbows, and if you've been holding Portillo's Inc. (NASDAQ: PTLO) stocks between September 19, 2023, and May 4, 2026, you might find yourself caught in a storm front. We're talking shareholder class action lawsuit, folks, thanks to some allegedly misguided management moves. This...

Continue Reading
InstaHeat 35K: FOGATTI Offers Upgraded RV Furnace Control

Updated Category News Views 318

Winter RV Trips Just Got Cozier There's nothing quite like hitting the open road in an RV during the winter months. But let's face it, nobody wants to return to a cabin that's as frigid as the great outdoors. Here's where FOGATTI steps up its game with the InstaHeat Ultra 35K RV Furnace. They’ve tinkered with the thermostat to iron out more precise control, just in time...

Continue Reading
Ambrosia Biosciences Unveils Promising Nonclinical Metabolic Data

Updated Category News Views 269

Ambrosia's Latest Nonclinical Revelations Ambrosia Biosciences has just thrown out some major bait at ObesityWeek® 2026. The highlight? New nonclinical data profiles for two of their understudy small molecule programs—AMB-895 and AMB-131. It may sound niche, but in this sector, promising data spins heads. Their GLP-1 receptor agonist, AMB-895, and GIP receptor...

Continue Reading
Uber Data Breach: Class Action Investigation Begins

Updated Category News Views 283

When Tech Meets Trouble: Uber's Data Breach Picture this: the hum of Uber rides weaving through your city, drivers none the wiser that personal info has been pried from the vaults thanks to their tech partner, Fireworks AI. Uber, folks, is in hot water once again. This isn’t just another tech hiccup; it's a legal whirlwind brewing up courtesy of Edelson Lechtzin LLP, a...

Continue Reading
WHO and RCSI Bahrain Join Forces on Health Initiatives

Updated Category News Views 406

Forging a Healthier Pathway In a world where healthcare challenges rise faster than my blood pressure during a stock market crash, the World Health Organization (WHO) and the Royal College of Surgeons in Ireland (RCSI) – Medical University of Bahrain have inked a deal to tackle these issues head-on. The memorandum of understanding (MoU) signed on November 15, 2026,...

Continue Reading
IDEAYA's IDE101: A New Front in Cancer Battle

Updated Category News Views 180

IDEAYA's Bold Move in Precision Medicine IDEAYA Biosciences, no stranger to the frontlines of cancer treatment, is gunning for a breakthrough with their latest pick, IDE101. They're jumping into the ring with a potential first-in-class inhibitor targeting CDKN2A-deficiency—a notorious player in the solid tumor game. They're not just mixing things up for the sake of it;...

Continue Reading
YONDELIS: Thai Approval Opens New Sarcoma Treatment Path

Updated Category News Views 103

New Hope for Thai Sarcoma Patients Alright, we’ve got some good news coming out of Thailand, folks. The Thai FDA just greenlit YONDELIS® (trabectedin) for those grappling with advanced soft tissue sarcoma (STS). Now, this isn’t your everyday drug release—it’s a clinical chess move packing potential for patients who’ve run out of other options. December 1st,...

Continue Reading
Investors Gear Up for Lennar Class Action Lawsuit

Updated Category News Views 235

High Stakes and Hard Hits for Lennar Stockholders There’s rarely a dull moment in the world of Wall Street, and Lennar Corporation (NYSE: LEN) is proving that rule right now. As a whiff of scandal wafts through the air, the famed homebuilder and its bigwigs are staring down the barrel of a formidable class action lawsuit. The question is, just how deep do the alleged...

Continue Reading

Top 5 Most Recently Viewed Articles

Kulicke & Soffa Announces Conference Call for Fiscal Results

Updated Category News Views 122

Kulicke & Soffa Schedules Conference Call Kulicke and Soffa Industries, Inc. (NASDAQ: KLIC), a leading name in semiconductor assembly technology, has announced a conference call to discuss its third fiscal quarter financial results and business outlook. The call is set for a future date, highlighting the company's commitment to transparency and communication with its...

Continue Reading
ARMOUR Residential REIT Launches Major Stock Offering for Growth

Updated Category News Views 162

ARMOUR Residential REIT Enters Public Stock Offering ARMOUR Residential REIT, Inc. (NYSE: ARR and ARR-PRC) has officially announced an underwritten public offering of 18,500,000 shares of common stock. The company is poised to grant underwriters an additional option to purchase up to 2,775,000 shares, making this a significant move for ARMOUR as it aims to enhance its...

Continue Reading
Celebrate Mother's Day with a Unique Brunch at Cannon + Belle

Updated Category News Views 195

Cannon + Belle Offers a Memorable Mother's Day Brunch Cannon + Belle at Hilton Austin is excited to announce an elevated Mother's Day brunch that promises to create unforgettable memories. This year, the restaurant will be hosting a special brunch event aimed at honoring mothers and all they do. With an impressive menu curated by the talented Chef Gereamy Cater, guests...

Continue Reading
Figma's Shares Surge in IPO But Valuation Remains a Concern

Updated Category News Views 244

Figma's Impressive IPO Performance Figma Inc. (NYSE: FIG) has captured significant investor attention following its explosive debut in the stock market. After launching its initial public offering, the company's shares skyrocketed by over 250%, marking a remarkable milestone for the firm. The stock began trading at a price of $33 per share, leading to approximately $1.2...

Continue Reading
Journey Medical Corporation's Emrosi Launch for Rosacea Relief

Updated Category News Views 215

Journey Medical Corporation Introduces Emrosi for Rosacea Treatment Journey Medical Corporation, a key player in the dermatological pharmaceutical industry, has recently launched Emrosi™ (40 mg Minocycline Hydrochloride Modified-Release Capsules), designed for the effective treatment of rosacea. The product, featuring a unique formulation of 10 mg immediate release and...

Continue Reading